A 6 ‐month randomized, double‐blind, placebo‐controlled trial of weekly exenatide in adolescents with obesity

ConclusionsTreatment of adolescents with severe obesity with extended ‐release exenatide is generally well tolerated and leads to a modest reduction in BMI metrics and improvement in glucose tolerance and cholesterol. The study indicates that the treatment provides additional beneficial effects beyond BMI reduction for the patient group.

Source: Pediatric Obesity - February 17, 2020 Category: Eating Disorders & Weight Management Authors: D. Weghuber, A. Forslund, H. Ahlstr öm, A. Alderborn, K. Bergström, S. Brunner, J. Cadamuro, I. Ciba, M. Dahlbom, V. Heu, J. Hofmann, H. Kristinsson, J. Kullberg, A. Ladinger, F. B. Lagler, M. Lidström, H. Manell, M. Meirik, K. Mörwa Tags: ORIGINAL RESEARCH Source Type: research